25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

LLY (Eli Lilly and Company) Stock Analysis
Buy, Hold or Sell?

Let's analyze Eli Lilly and Company together

I guess you are interested in Eli Lilly and Company. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Eli Lilly and Company’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Eli Lilly and Company’s Price Targets

I'm going to help you getting a better view of Eli Lilly and Company. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Eli Lilly and Company

I send you an email if I find something interesting about Eli Lilly and Company.

1. Quick Overview

1.1. Quick analysis of Eli Lilly and Company (30 sec.)










1.2. What can you expect buying and holding a share of Eli Lilly and Company? (30 sec.)

How much money do you get?

How much money do you get?
€5.60
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
€17.45
Expected worth in 1 year
€21.98
How sure are you?
100.0%

+ What do you gain per year?

Total Gains per Share
€9.31
Return On Investment
1.3%

For what price can you sell your share?

Current Price per Share
€715.30
Expected price per share
€612.10 - €799.72
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Eli Lilly and Company (5 min.)




Live pricePrice per Share (EOD)
€715.30
Intrinsic Value Per Share
€40.07 - €48.36
Total Value Per Share
€57.52 - €65.81

2.2. Growth of Eli Lilly and Company (5 min.)




Is Eli Lilly and Company growing?

Current yearPrevious yearGrowGrow %
How rich?$18.3b$12.1b$3.5b22.4%

How much money is Eli Lilly and Company making?

Current yearPrevious yearGrowGrow %
Making money$3.4b$1.8b$1.6b46.8%
Net Profit Margin24.8%18.7%--

How much money comes from the company's main activities?

2.3. Financial Health of Eli Lilly and Company (5 min.)




2.4. Comparing to competitors in the Other industry (5 min.)




  Industry Rankings (Other)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Eli Lilly and Company?

Welcome investor! Eli Lilly and Company's management wants to use your money to grow the business. In return you get a share of Eli Lilly and Company.

First you should know what it really means to hold a share of Eli Lilly and Company. And how you can make/lose money.

Speculation

The Price per Share of Eli Lilly and Company is €715.30. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Eli Lilly and Company.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Eli Lilly and Company, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €17.45. Based on the TTM, the Book Value Change Per Share is €1.13 per quarter. Based on the YOY, the Book Value Change Per Share is €0.72 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €1.19 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Eli Lilly and Company.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 β‚¬% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share
Usd Eps6.310.9%3.840.5%2.040.3%2.530.4%2.140.3%1.820.3%
Usd Book Value Change Per Share2.810.4%1.330.2%0.850.1%0.950.1%0.800.1%0.890.1%
Usd Dividend Per Share1.500.2%1.400.2%1.200.2%1.200.2%1.050.1%1.000.1%
Usd Total Gains Per Share4.310.6%2.730.4%2.050.3%2.150.3%1.840.3%1.890.3%
Usd Price Per Share771.89-867.18-765.67-683.05-505.45-406.25-
Price to Earnings Ratio30.57-90.71--554.11--133.96--63.47--45.94-
Price-to-Total Gains Ratio179.08-395.51-416.55-369.48-492.80-439.50-
Price to Book Ratio37.72-50.42-56.60-47.82-40.74-36.35-
Price-to-Total Gains Ratio179.08-395.51-416.55-369.48-492.80-439.50-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share838.97537
Number of shares1
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share1.401.05
Usd Book Value Change Per Share1.330.80
Usd Total Gains Per Share2.731.84
Gains per Quarter (1 shares)2.731.84
Gains per Year (1 shares)10.927.38
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
165143-3
2111112864
3171623131011
4222134171318
5282745211625
6343256251932
7393767292239
8454378332646
9504889382953
105653100423260

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%11.01.00.091.7%19.01.00.095.0%22.01.00.095.7%22.01.00.095.7%
Book Value Change Per Share3.01.00.075.0%10.02.00.083.3%16.04.00.080.0%19.04.00.082.6%19.04.00.082.6%
Dividend per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%23.00.00.0100.0%23.00.00.0100.0%
Total Gains per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%23.00.00.0100.0%23.00.00.0100.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Eli Lilly and Company compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--2.3941.133+111%0.725+230%0.806+197%0.682+251%0.759+216%
Book Value Per Share--17.44614.907+17%11.396+53%12.014+45%9.880+77%7.948+119%
Current Ratio--1.2781.269+1%1.114+15%1.178+8%1.217+5%1.202+6%
Debt To Asset Ratio--0.8180.818+0%0.811+1%0.806+2%0.8200%0.843-3%
Debt To Equity Ratio--4.5194.507+0%4.341+4%4.202+8%4.799-6%6.496-30%
Dividend Per Share--1.2811.195+7%1.024+25%1.024+25%0.891+44%0.850+51%
Enterprise Value--519795373850.000603890182100.000-14%549244705057.500-5%485257516701.667+7%355458591419.000+46%321027517013.913+62%
Eps--5.3823.278+64%1.740+209%2.159+149%1.820+196%1.550+247%
Ev To Sales Ratio--9.79613.583-28%16.510-41%14.024-30%11.109-12%10.265-5%
Free Cash Flow Per Share--1.220-0.011+101%-0.837+169%-0.043+104%0.411+197%0.502+143%
Free Cash Flow To Equity Per Share--0.0360.017+114%0.426-91%0.161-78%0.145-75%0.166-78%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--48.361----------
Intrinsic Value_10Y_min--40.074----------
Intrinsic Value_1Y_max--0.556----------
Intrinsic Value_1Y_min--0.544----------
Intrinsic Value_3Y_max--4.941----------
Intrinsic Value_3Y_min--4.651----------
Intrinsic Value_5Y_max--13.267----------
Intrinsic Value_5Y_min--12.032----------
Market Cap--590205797300.000663972489975.000-11%593805975675.000-1%531617671662.500+11%396763895302.500+49%319438512904.231+85%
Net Profit Margin--0.3640.248+47%0.187+95%0.218+67%0.214+70%0.244+49%
Operating Margin----0%-0%-0%0.036-100%0.103-100%
Operating Ratio--0.6990.748-6%0.841-17%0.845-17%0.896-22%0.909-23%
Pb Ratio41.000+8%37.72250.422-25%56.596-33%47.824-21%40.735-7%36.354+4%
Pe Ratio33.227+8%30.57090.707-66%-554.106+1913%-133.958+538%-63.467+308%-45.944+250%
Price Per Share715.300+8%658.100739.350-11%652.800+1%582.358+13%430.939+53%346.368+90%
Price To Free Cash Flow Ratio146.594+8%134.872-43.545+132%1427.737-91%434.302-69%285.980-53%233.621-42%
Price To Total Gains Ratio194.643+8%179.078395.512-55%416.547-57%369.477-52%492.804-64%439.495-59%
Quick Ratio--0.3680.397-7%0.389-6%0.406-10%0.420-13%0.416-12%
Return On Assets--0.0560.039+44%0.027+105%0.033+71%0.032+75%0.036+57%
Return On Equity--0.3100.216+43%0.148+109%0.172+80%0.187+65%0.296+5%
Total Gains Per Share--3.6752.328+58%1.748+110%1.830+101%1.573+134%1.608+128%
Usd Book Value--18351518961.85315699119342.102+17%12177605162.080+51%12908176460.599+42%10736005141.000+71%8991365944.762+104%
Usd Book Value Change Per Share--2.8081.329+111%0.850+230%0.946+197%0.800+251%0.890+216%
Usd Book Value Per Share--20.46317.484+17%13.366+53%14.091+45%11.588+77%9.323+119%
Usd Dividend Per Share--1.5021.401+7%1.201+25%1.201+25%1.045+44%0.997+51%
Usd Enterprise Value--609667993988.665708302794585.090-14%644209114561.942-5%569158541339.385+7%416917381875.345+46%376533174705.619+62%
Usd Eps--6.3123.845+64%2.040+209%2.532+149%2.135+196%1.818+247%
Usd Free Cash Flow--1283169137.890-12551654.467+101%-907144573.106+171%-38913462.619+103%466036429.484+175%572610092.623+124%
Usd Free Cash Flow Per Share--1.431-0.013+101%-0.982+169%-0.050+104%0.482+197%0.588+143%
Usd Free Cash Flow To Equity Per Share--0.0420.020+114%0.499-91%0.189-78%0.170-75%0.195-78%
Usd Market Cap--692252379653.170778773333491.678-11%696475028869.208-1%623534367092.946+11%465364372800.302+49%374669431785.372+85%
Usd Price Per Share838.975+8%771.885867.184-11%765.669+1%683.048+13%505.448+53%406.255+90%
Usd Profit--5661246223.7153450429810.204+64%1835791980.557+208%2303603644.039+146%1970354717.624+187%1945979581.596+191%
Usd Revenue--15559750971.59113316280253.831+17%9731982798.181+60%10142703603.034+53%8875839947.746+75%8123074569.921+92%
Usd Total Gains Per Share--4.3102.730+58%2.051+110%2.147+101%1.845+134%1.886+128%
 EOD+2 -4MRQTTM+26 -11YOY+24 -133Y+28 -95Y+30 -810Y+29 -9

3.3 Fundamental Score

Let's check the fundamental score of Eli Lilly and Company based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1533.227
Price to Book Ratio (EOD)Between0-141.000
Net Profit Margin (MRQ)Greater than00.364
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.368
Current Ratio (MRQ)Greater than11.278
Debt to Asset Ratio (MRQ)Less than10.818
Debt to Equity Ratio (MRQ)Less than14.519
Return on Equity (MRQ)Greater than0.150.310
Return on Assets (MRQ)Greater than0.050.056
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of Eli Lilly and Company based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5073.728
Ma 20Greater thanMa 50644.795
Ma 50Greater thanMa 100628.242
Ma 100Greater thanMa 200648.019
OpenGreater thanClose698.600
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About Eli Lilly and Company

  • Other
  • 0

There is no Profile data available for LLY.SG.

Fundamental data was last updated by Penke on 2025-10-01 18:17:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Eli Lilly and Company earns for each €1 of revenue.

  • Above 10% is considered healthy but always compareΒ Eli Lilly and Company to theΒ Other industry mean.
  • A Net Profit Margin of 36.4%Β means thatΒ €0.36 for each €1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Eli Lilly and Company:

  • The MRQ is 36.4%. The company is making a huge profit. +2
  • The TTM is 24.8%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ36.4%TTM24.8%+11.6%
TTM24.8%YOY18.7%+6.1%
TTM24.8%5Y21.4%+3.3%
5Y21.4%10Y24.4%-2.9%
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ36.4%6.4%+30.0%
TTM24.8%5.8%+19.0%
YOY18.7%5.7%+13.0%
3Y21.8%5.9%+15.9%
5Y21.4%6.0%+15.4%
10Y24.4%5.7%+18.7%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Eli Lilly and Company is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Eli Lilly and Company to theΒ Other industry mean.
  • 5.6% Return on Assets means thatΒ Eli Lilly and Company generatedΒ €0.06 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Eli Lilly and Company:

  • The MRQ is 5.6%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 3.9%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ5.6%TTM3.9%+1.7%
TTM3.9%YOY2.7%+1.2%
TTM3.9%5Y3.2%+0.7%
5Y3.2%10Y3.6%-0.4%
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ5.6%1.4%+4.2%
TTM3.9%1.2%+2.7%
YOY2.7%1.1%+1.6%
3Y3.3%1.1%+2.2%
5Y3.2%1.3%+1.9%
10Y3.6%1.3%+2.3%
4.3.1.3. Return on Equity

Shows how efficient Eli Lilly and Company is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Eli Lilly and Company to theΒ Other industry mean.
  • 31.0% Return on Equity means Eli Lilly and Company generated €0.31Β for eachΒ €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Eli Lilly and Company:

  • The MRQ is 31.0%. Using its investors money, the company is very efficient in making profit. +2
  • The TTM is 21.6%. Using its investors money, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ31.0%TTM21.6%+9.4%
TTM21.6%YOY14.8%+6.8%
TTM21.6%5Y18.7%+2.8%
5Y18.7%10Y29.6%-10.9%
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ31.0%3.9%+27.1%
TTM21.6%3.7%+17.9%
YOY14.8%3.5%+11.3%
3Y17.2%3.5%+13.7%
5Y18.7%3.9%+14.8%
10Y29.6%3.7%+25.9%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Eli Lilly and Company.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Eli Lilly and Company is operatingΒ .

  • Measures how much profit Eli Lilly and Company makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Eli Lilly and Company to theΒ Other industry mean.
  • An Operating Margin of 0.0%Β means the company generated €0.00 Β for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Eli Lilly and Company:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y3.6%-3.6%
5Y3.6%10Y10.3%-6.7%
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ-9.9%-9.9%
TTM-9.9%-9.9%
YOY-3.2%-3.2%
3Y-2.5%-2.5%
5Y3.6%1.9%+1.7%
10Y10.3%5.7%+4.6%
4.3.2.2. Operating Ratio

Measures how efficient Eli Lilly and Company is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Other industry mean).
  • An Operation Ratio of 0.70 means that the operating costs are €0.70 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Eli Lilly and Company:

  • The MRQ is 0.699. The company is efficient in keeping operating costs low. +1
  • The TTM is 0.748. The company is efficient in keeping operating costs low. +1
Trends
Current periodCompared to+/- 
MRQ0.699TTM0.748-0.048
TTM0.748YOY0.841-0.094
TTM0.7485Y0.896-0.148
5Y0.89610Y0.909-0.013
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6991.233-0.534
TTM0.7481.217-0.469
YOY0.8411.265-0.424
3Y0.8451.262-0.417
5Y0.8961.245-0.349
10Y0.9091.287-0.378
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Eli Lilly and Company.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Eli Lilly and Company is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Other industry mean).
  • A Current Ratio of 1.28Β means the company has €1.28 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Eli Lilly and Company:

  • The MRQ is 1.278. The company is just able to pay all its short-term debts.
  • The TTM is 1.269. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.278TTM1.269+0.008
TTM1.269YOY1.114+0.155
TTM1.2695Y1.217+0.052
5Y1.21710Y1.202+0.015
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2781.394-0.116
TTM1.2691.402-0.133
YOY1.1141.415-0.301
3Y1.1781.483-0.305
5Y1.2171.553-0.336
10Y1.2021.505-0.303
4.4.3.2. Quick Ratio

Measures if Eli Lilly and Company is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Eli Lilly and Company to theΒ Other industry mean.
  • A Quick Ratio of 0.37Β means the company can pay off €0.37 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Eli Lilly and Company:

  • The MRQ is 0.368. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.397. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.368TTM0.397-0.030
TTM0.397YOY0.389+0.008
TTM0.3975Y0.420-0.023
5Y0.42010Y0.416+0.004
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3680.586-0.218
TTM0.3970.569-0.172
YOY0.3890.600-0.211
3Y0.4060.595-0.189
5Y0.4200.619-0.199
10Y0.4160.608-0.192
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Eli Lilly and Company.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of Eli Lilly and CompanyΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Eli Lilly and Company to Other industry mean.
  • A Debt to Asset Ratio of 0.82Β means that Eli Lilly and Company assets areΒ financed with 81.8% credit (debt) and the remaining percentage (100% - 81.8%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Eli Lilly and Company:

  • The MRQ is 0.818. The company is just able to pay all its debts by selling its assets.
  • The TTM is 0.818. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ0.818TTM0.818+0.001
TTM0.818YOY0.811+0.007
TTM0.8185Y0.820-0.002
5Y0.82010Y0.843-0.023
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8180.525+0.293
TTM0.8180.521+0.297
YOY0.8110.534+0.277
3Y0.8060.534+0.272
5Y0.8200.544+0.276
10Y0.8430.549+0.294
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Eli Lilly and Company is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Eli Lilly and Company to theΒ Other industry mean.
  • A Debt to Equity ratio of 451.9% means that company has €4.52 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Eli Lilly and Company:

  • The MRQ is 4.519. The company is unable to pay all its debts with equity. -1
  • The TTM is 4.507. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ4.519TTM4.507+0.012
TTM4.507YOY4.341+0.166
TTM4.5075Y4.799-0.292
5Y4.79910Y6.496-1.697
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ4.5191.040+3.479
TTM4.5071.040+3.467
YOY4.3411.118+3.223
3Y4.2021.162+3.040
5Y4.7991.235+3.564
10Y6.4961.321+5.175
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every €1 in earnings Eli Lilly and Company generates.

  • Above 15 is considered overpriced butΒ always compareΒ Eli Lilly and Company to theΒ Other industry mean.
  • A PE ratio of 30.57 means the investor is paying €30.57Β for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Eli Lilly and Company:

  • The EOD is 33.227. Based on the earnings, the company is overpriced. -1
  • The MRQ is 30.570. Based on the earnings, the company is overpriced. -1
  • The TTM is 90.707. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD33.227MRQ30.570+2.657
MRQ30.570TTM90.707-60.137
TTM90.707YOY-554.106+644.813
TTM90.7075Y-63.467+154.174
5Y-63.46710Y-45.944-17.523
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
EOD33.22716.325+16.902
MRQ30.57015.985+14.585
TTM90.70715.188+75.519
YOY-554.10613.623-567.729
3Y-133.95811.859-145.817
5Y-63.46714.426-77.893
10Y-45.94414.212-60.156
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Eli Lilly and Company:

  • The EOD is 146.594. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is 134.872. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -43.545. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD146.594MRQ134.872+11.723
MRQ134.872TTM-43.545+178.417
TTM-43.545YOY1,427.737-1,471.282
TTM-43.5455Y285.980-329.525
5Y285.98010Y233.621+52.359
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
EOD146.5949.319+137.275
MRQ134.8728.039+126.833
TTM-43.5457.777-51.322
YOY1,427.7376.115+1,421.622
3Y434.3023.353+430.949
5Y285.9803.940+282.040
10Y233.6214.073+229.548
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Eli Lilly and Company is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Other industry mean).
  • A PB ratio of 37.72 means the investor is paying €37.72Β for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Eli Lilly and Company:

  • The EOD is 41.000. Based on the equity, the company is expensive. -2
  • The MRQ is 37.722. Based on the equity, the company is expensive. -2
  • The TTM is 50.422. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD41.000MRQ37.722+3.279
MRQ37.722TTM50.422-12.700
TTM50.422YOY56.596-6.174
TTM50.4225Y40.735+9.687
5Y40.73510Y36.354+4.381
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
EOD41.0001.775+39.225
MRQ37.7221.632+36.090
TTM50.4221.538+48.884
YOY56.5961.496+55.100
3Y47.8241.608+46.216
5Y40.7351.902+38.833
10Y36.3541.822+34.532
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2025-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets100,922,600
Total Liabilities82,573,500
Total Stockholder Equity18,272,900
 As reported
Total Liabilities 82,573,500
Total Stockholder Equity+ 18,272,900
Total Assets = 100,922,600

Assets

Total Assets100,922,600
Total Current Assets49,854,000
Long-term Assets51,068,600
Total Current Assets
Cash And Cash Equivalents 3,375,900
Short-term Investments 170,100
Net Receivables 14,170,400
Inventory 11,013,800
Other Current Assets 68,800
Total Current Assets  (as reported)49,854,000
Total Current Assets  (calculated)28,799,000
+/- 21,055,000
Long-term Assets
Property Plant Equipment 20,529,700
Goodwill 5,770,500
Long Term Investments 3,207,400
Intangible Assets 5,908,300
Long-term Assets Other 6,225,300
Long-term Assets  (as reported)51,068,600
Long-term Assets  (calculated)41,641,200
+/- 9,427,400

Liabilities & Shareholders' Equity

Total Current Liabilities39,019,900
Long-term Liabilities43,553,600
Total Stockholder Equity18,272,900
Total Current Liabilities
Short Long Term Debt 5,723,700
Accounts payable 4,075,700
Other Current Liabilities 5,076,900
Total Current Liabilities  (as reported)39,019,900
Total Current Liabilities  (calculated)14,876,300
+/- 24,143,600
Long-term Liabilities
Long term Debt 34,180,100
Long-term Liabilities Other 2,344,700
Long-term Liabilities  (as reported)43,553,600
Long-term Liabilities  (calculated)36,524,800
+/- 7,028,800
Total Stockholder Equity
Retained Earnings 17,376,200
Total Stockholder Equity (as reported)18,272,900
Total Stockholder Equity (calculated)17,376,200
+/- 896,700
Other
Capital Stock592,000
Common Stock Shares Outstanding 896,833
Net Debt 36,527,900
Net Invested Capital 58,176,700
Net Working Capital 10,834,100
Property Plant and Equipment Gross 33,083,700



6.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-31
> Total Assets 
38,006,800
38,666,400
37,893,100
39,286,100
41,102,800
41,967,000
43,946,000
46,633,100
46,838,300
47,809,000
48,187,000
48,806,000
46,919,300
47,063,600
47,461,500
49,489,800
53,163,000
54,814,000
57,915,500
64,006,300
63,943,500
71,874,800
75,606,900
78,714,900
89,388,800
100,922,600
100,922,60089,388,80078,714,90075,606,90071,874,80063,943,50064,006,30057,915,50054,814,00053,163,00049,489,80047,461,50047,063,60046,919,30048,806,00048,187,00047,809,00046,838,30046,633,10043,946,00041,967,00041,102,80039,286,10037,893,10038,666,40038,006,800
   > Total Current Assets 
12,597,500
13,454,500
12,661,800
13,709,600
13,994,200
14,581,900
16,239,900
17,462,100
16,604,500
17,295,500
17,808,300
18,452,400
16,964,700
17,115,200
17,639,900
18,034,500
20,811,400
21,331,600
23,007,000
25,727,000
25,188,800
30,204,300
31,415,100
32,739,700
41,261,200
49,854,000
49,854,00041,261,20032,739,70031,415,10030,204,30025,188,80025,727,00023,007,00021,331,60020,811,40018,034,50017,639,90017,115,20016,964,70018,452,40017,808,30017,295,50016,604,50017,462,10016,239,90014,581,90013,994,20013,709,60012,661,80013,454,50012,597,500
       Cash And Cash Equivalents 
2,036,400
2,290,200
1,563,800
2,337,500
1,699,000
2,365,100
3,595,300
3,657,100
3,002,400
3,220,000
3,788,200
3,818,500
2,459,200
2,622,900
2,617,400
2,067,000
3,545,900
2,694,500
2,380,800
2,818,600
2,460,200
3,223,600
3,369,000
3,268,400
3,093,300
3,375,900
3,375,9003,093,3003,268,4003,369,0003,223,6002,460,2002,818,6002,380,8002,694,5003,545,9002,067,0002,617,4002,622,9002,459,2003,818,5003,788,2003,220,0003,002,4003,657,1003,595,3002,365,1001,699,0002,337,5001,563,8002,290,2002,036,400
       Short-term Investments 
100,700
77,700
89,200
101,000
78,400
22,800
35,000
24,200
49,000
51,200
37,100
90,100
109,100
113,800
124,700
144,800
123,400
134,600
113,100
109,100
126,100
140,400
149,400
154,800
127,400
170,100
170,100127,400154,800149,400140,400126,100109,100113,100134,600123,400144,800124,700113,800109,10090,10037,10051,20049,00024,20035,00022,80078,400101,00089,20077,700100,700
       Net Receivables 
4,200,500
4,612,500
4,441,700
4,547,300
5,106,100
4,828,900
4,886,700
5,875,300
5,592,800
5,829,400
5,914,300
6,672,800
6,322,500
6,364,500
6,715,300
6,896,000
7,526,200
7,516,100
8,167,100
9,090,500
7,885,600
11,027,900
10,294,800
11,005,700
12,036,600
14,170,400
14,170,40012,036,60011,005,70010,294,80011,027,9007,885,6009,090,5008,167,1007,516,1007,526,2006,896,0006,715,3006,364,5006,322,5006,672,8005,914,3005,829,4005,592,8005,875,3004,886,7004,828,9005,106,1004,547,3004,441,7004,612,5004,200,500
       Inventory 
3,055,200
3,181,100
3,101,300
3,190,700
3,102,400
3,313,900
3,555,400
3,980,300
3,660,800
3,824,900
3,907,400
3,886,000
3,893,000
3,899,400
3,831,100
4,309,700
4,544,800
4,798,700
4,901,400
5,772,800
6,101,800
6,481,500
7,459,800
7,589,200
9,311,000
11,013,800
11,013,8009,311,0007,589,2007,459,8006,481,5006,101,8005,772,8004,901,4004,798,7004,544,8004,309,7003,831,1003,899,4003,893,0003,886,0003,907,4003,824,9003,660,8003,980,3003,555,4003,313,9003,102,4003,190,7003,101,3003,181,1003,055,200
   > Long-term Assets 
25,409,300
25,211,900
25,231,300
25,576,500
27,108,600
27,385,100
27,706,100
29,171,000
30,233,800
30,513,500
30,378,700
30,353,600
29,954,600
29,948,400
29,821,600
31,455,300
32,351,600
33,482,400
34,908,500
38,279,300
38,754,700
41,670,500
44,191,800
45,975,200
48,127,600
51,068,600
51,068,60048,127,60045,975,20044,191,80041,670,50038,754,70038,279,30034,908,50033,482,40032,351,60031,455,30029,821,60029,948,40029,954,60030,353,60030,378,70030,513,50030,233,80029,171,00027,706,10027,385,10027,108,60025,576,50025,231,30025,211,90025,409,300
       Property Plant Equipment 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9,311,300
10,144,000
10,546,200
11,277,400
11,863,200
12,913,600
13,624,000
14,829,400
16,171,800
17,102,400
18,474,100
20,529,700
20,529,70018,474,10017,102,40016,171,80014,829,40013,624,00012,913,60011,863,20011,277,40010,546,20010,144,0009,311,30000000000000000
       Goodwill 
3,855,900
3,820,100
3,772,500
3,679,400
3,779,100
3,723,200
3,726,400
3,766,500
3,877,400
3,884,200
3,884,100
3,892,000
3,892,000
3,891,800
3,891,600
4,073,000
4,073,100
4,078,900
4,085,200
4,939,700
4,939,600
5,768,200
5,768,400
5,770,300
5,770,500
5,770,500
5,770,5005,770,5005,770,3005,768,4005,768,2004,939,6004,939,7004,085,2004,078,9004,073,1004,073,0003,891,6003,891,8003,892,0003,892,0003,884,1003,884,2003,877,4003,766,5003,726,4003,723,2003,779,1003,679,4003,772,5003,820,1003,855,900
       Long Term Investments 
2,111,400
1,852,700
1,825,300
1,962,400
2,148,700
2,406,400
2,476,200
2,966,800
3,232,400
3,474,900
3,350,500
3,212,600
2,727,300
2,587,200
2,574,600
2,901,800
2,750,400
2,745,100
2,691,700
3,052,200
3,086,900
2,877,600
3,200,200
3,215,900
3,222,700
3,207,400
3,207,4003,222,7003,215,9003,200,2002,877,6003,086,9003,052,2002,691,7002,745,1002,750,4002,901,8002,574,6002,587,2002,727,3003,212,6003,350,5003,474,9003,232,4002,966,8002,476,2002,406,4002,148,7001,962,4001,825,3001,852,7002,111,400
       Intangible Assets 
6,641,500
6,586,600
6,689,300
6,618,000
7,766,700
7,712,500
7,588,600
7,450,000
8,087,800
7,985,400
7,887,700
7,691,900
7,482,400
7,497,700
7,124,100
7,206,600
7,087,100
6,903,500
6,781,700
6,906,600
6,762,200
6,636,100
6,537,300
6,166,300
6,012,200
5,908,300
5,908,3006,012,2006,166,3006,537,3006,636,1006,762,2006,906,6006,781,7006,903,5007,087,1007,206,6007,124,1007,497,7007,482,4007,691,9007,887,7007,985,4008,087,8007,450,0007,588,6007,712,5007,766,7006,618,0006,689,3006,586,6006,641,500
       Long-term Assets Other 
1,963,000
2,052,100
2,194,200
2,339,100
3,044,600
3,080,100
3,078,500
3,475,400
3,756,200
3,638,600
3,710,400
4,082,700
4,285,300
4,471,600
4,535,700
4,337,000
4,488,100
4,671,600
4,911,900
4,989,900
4,708,100
4,903,900
5,121,800
5,719,700
6,074,900
6,225,300
6,225,3006,074,9005,719,7005,121,8004,903,9004,708,1004,989,9004,911,9004,671,6004,488,1004,337,0004,535,7004,471,6004,285,3004,082,7003,710,4003,638,6003,756,2003,475,4003,078,5003,080,1003,044,6002,339,1002,194,2002,052,1001,963,000
> Total Liabilities 
35,441,800
35,809,100
34,430,800
36,587,000
37,905,600
37,695,000
38,950,000
40,807,900
39,739,000
41,145,500
40,232,900
39,651,200
37,457,300
38,404,400
37,295,600
38,714,400
41,868,100
43,664,700
46,608,100
53,142,600
51,046,100
58,239,300
61,286,200
64,443,300
73,542,000
82,573,500
82,573,50073,542,00064,443,30061,286,20058,239,30051,046,10053,142,60046,608,10043,664,70041,868,10038,714,40037,295,60038,404,40037,457,30039,651,20040,232,90041,145,50039,739,00040,807,90038,950,00037,695,00037,905,60036,587,00034,430,80035,809,10035,441,800
   > Total Current Liabilities 
11,236,100
11,855,400
10,828,600
11,775,200
12,610,200
11,988,500
11,976,900
12,481,600
11,714,200
15,093,200
13,682,000
15,052,700
13,386,000
15,620,600
15,652,800
17,138,200
16,010,000
18,915,000
21,998,200
27,293,200
18,598,100
27,121,200
24,674,100
28,376,600
30,068,100
39,019,900
39,019,90030,068,10028,376,60024,674,10027,121,20018,598,10027,293,20021,998,20018,915,00016,010,00017,138,20015,652,80015,620,60013,386,00015,052,70013,682,00015,093,20011,714,20012,481,60011,976,90011,988,50012,610,20011,775,20010,828,60011,855,40011,236,100
       Short-term Debt 
2,354,900
2,068,600
1,563,100
1,499,300
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000001,499,3001,563,1002,068,6002,354,900
       Short Long Term Debt 
2,354,900
2,068,600
1,563,100
1,499,300
3,248,000
1,263,800
587,500
8,700
4,900
1,778,500
1,563,000
1,538,300
1,355,900
2,121,800
1,744,600
1,501,100
3,100
661,600
2,244,700
6,904,500
1,651,500
5,161,600
2,074,300
5,117,100
4,016,400
5,723,700
5,723,7004,016,4005,117,1002,074,3005,161,6001,651,5006,904,5002,244,700661,6003,1001,501,1001,744,6002,121,8001,355,9001,538,3001,563,0001,778,5004,9008,700587,5001,263,8003,248,0001,499,3001,563,1002,068,6002,354,900
       Accounts payable 
1,168,100
1,198,900
1,114,900
1,405,300
1,207,700
1,247,200
1,430,100
1,606,700
1,639,600
1,597,800
1,566,800
1,670,600
1,433,300
1,659,300
1,683,200
1,930,600
2,015,900
2,474,200
2,435,100
2,598,800
2,473,700
2,924,800
2,886,500
3,228,600
3,442,000
4,075,700
4,075,7003,442,0003,228,6002,886,5002,924,8002,473,7002,598,8002,435,1002,474,2002,015,9001,930,6001,683,2001,659,3001,433,3001,670,6001,566,8001,597,8001,639,6001,606,7001,430,1001,247,2001,207,7001,405,3001,114,9001,198,9001,168,100
       Other Current Liabilities 
2,254,300
2,189,200
1,988,400
2,189,400
2,217,400
2,060,900
2,245,000
2,750,300
2,806,800
2,624,900
2,326,500
3,027,500
2,536,700
2,003,500
1,986,900
2,845,400
2,193,500
2,271,600
2,585,400
3,281,300
4,199,100
4,249,200
5,580,300
5,051,400
3,769,800
5,076,900
5,076,9003,769,8005,051,4005,580,3004,249,2004,199,1003,281,3002,585,4002,271,6002,193,5002,845,4001,986,9002,003,5002,536,7003,027,5002,326,5002,624,9002,806,8002,750,3002,245,0002,060,9002,217,4002,189,4001,988,4002,189,2002,254,300
   > Long-term Liabilities 
24,205,700
23,953,700
23,602,200
24,811,800
25,295,400
25,706,500
26,973,100
28,326,300
28,024,800
26,052,300
26,550,900
24,598,500
24,071,300
22,783,800
21,642,800
21,576,200
25,858,100
24,749,700
24,609,900
25,849,400
32,448,000
31,118,100
36,612,100
36,066,700
43,473,900
43,553,600
43,553,60043,473,90036,066,70036,612,10031,118,10032,448,00025,849,40024,609,90024,749,70025,858,10021,576,20021,642,80022,783,80024,071,30024,598,50026,550,90026,052,30028,024,80028,326,30026,973,10025,706,50025,295,40024,811,80023,602,20023,953,70024,205,700
       Long term Debt 
13,610,200
13,717,600
13,662,200
13,817,900
13,982,300
15,064,400
16,334,600
16,586,600
16,199,600
14,736,600
15,522,400
15,346,400
15,152,900
14,692,000
14,143,800
14,737,500
18,880,500
18,158,400
17,923,600
18,320,800
24,559,900
23,730,400
29,045,400
28,527,100
34,499,500
34,180,100
34,180,10034,499,50028,527,10029,045,40023,730,40024,559,90018,320,80017,923,60018,158,40018,880,50014,737,50014,143,80014,692,00015,152,90015,346,40015,522,40014,736,60016,199,60016,586,60016,334,60015,064,40013,982,30013,817,90013,662,20013,717,60013,610,200
       Capital Lease Obligations 
508,200
503,300
485,200
486,700
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000486,700485,200503,300508,200
       Long-term Liabilities Other 
1,169,800
1,142,800
1,100,400
1,014,300
1,873,000
1,826,800
1,702,600
1,707,500
1,737,300
1,801,900
1,748,700
1,644,300
1,713,900
1,783,100
1,852,900
1,824,000
1,822,500
1,951,800
1,906,100
2,240,600
2,270,800
2,470,700
2,239,400
2,178,200
2,288,400
2,344,700
2,344,7002,288,4002,178,2002,239,4002,470,7002,270,8002,240,6001,906,1001,951,8001,822,5001,824,0001,852,9001,783,1001,713,9001,644,3001,748,7001,801,9001,737,3001,707,5001,702,6001,826,8001,873,0001,014,3001,100,4001,142,8001,169,800
> Total Stockholder Equity
2,480,300
2,780,500
3,382,500
2,606,900
3,078,800
4,092,900
4,826,900
5,641,600
6,898,700
6,444,400
7,757,000
8,979,200
9,330,800
8,544,700
10,070,100
10,649,800
11,190,400
11,063,800
11,220,400
10,771,900
12,812,200
13,562,000
14,240,000
14,192,100
15,764,800
18,272,900
18,272,90015,764,80014,192,10014,240,00013,562,00012,812,20010,771,90011,220,40011,063,80011,190,40010,649,80010,070,1008,544,7009,330,8008,979,2007,757,0006,444,4006,898,7005,641,6004,826,9004,092,9003,078,8002,606,9003,382,5002,780,5002,480,300
   Common Stock00000000000000000000000000
   Retained Earnings 
4,879,400
4,318,100
4,981,900
4,920,400
5,879,400
6,617,200
7,154,000
7,830,200
9,181,300
8,530,100
9,639,400
8,958,500
9,369,400
8,556,000
10,006,500
10,042,600
10,639,300
10,368,500
10,309,900
10,312,300
12,553,900
13,178,000
13,627,200
13,545,000
15,099,500
17,376,200
17,376,20015,099,50013,545,00013,627,20013,178,00012,553,90010,312,30010,309,90010,368,50010,639,30010,042,60010,006,5008,556,0009,369,4008,958,5009,639,4008,530,1009,181,3007,830,2007,154,0006,617,2005,879,4004,920,4004,981,9004,318,1004,879,400
   Capital Surplus 00000000000000000000000000
   Treasury Stock00000000000000000000000000
   Other Stockholders Equity 00000000000000000000000000



6.3. Balance Sheets

Currency in USD. All numbers in thousands.




6.4. Cash Flows

Currency in USD. All numbers in thousands.




6.5. Income Statements

Currency in USD. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue45,042,700
Cost of Revenue-8,418,300
Gross Profit36,624,40036,624,400
 
Operating Income (+$)
Gross Profit36,624,400
Operating Expense-27,541,000
Operating Income17,501,7009,083,400
 
Operating Expense (+$)
Research Development10,990,600
Selling General Administrative8,132,100
Selling And Marketing Expenses0
Operating Expense27,541,00019,122,700
 
Net Interest Income (+$)
Interest Income175,200
Interest Expense-780,600
Other Finance Cost-0
Net Interest Income-605,400
 
Pretax Income (+$)
Operating Income17,501,700
Net Interest Income-605,400
Other Non-Operating Income Expenses0
Income Before Tax (EBT)12,680,40021,717,600
EBIT - interestExpense = -780,600
10,590,000
11,370,600
Interest Expense780,600
Earnings Before Interest and Taxes (EBIT)013,461,000
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax12,680,400
Tax Provision-2,090,400
Net Income From Continuing Ops10,590,00010,590,000
Net Income10,590,000
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net-4,215,900605,400
 

Technical Analysis of Eli Lilly and Company
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Eli Lilly and Company. The general trend of Eli Lilly and Company is BULLISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Eli Lilly and Company's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (14.3%) Bearish trend (-14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Eli Lilly and Company Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Eli Lilly and Company.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 783.88 < 786.67 < 799.72.

The bearish price targets are: 705.74 > 654.60 > 612.10.

Know someone who trades $LLY? Share this with them.πŸ‘‡

Eli Lilly and Company Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Eli Lilly and Company. The current mas is .

The long score for the Moving Averages is 8/14.
The longshort score for the Moving Averages is 2/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Eli Lilly and Company Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Eli Lilly and Company. The current macd is 13.94.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Eli Lilly and Company price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Eli Lilly and Company. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Eli Lilly and Company price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Eli Lilly and Company Daily Moving Average Convergence/Divergence (MACD) ChartEli Lilly and Company Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Eli Lilly and Company. The current adx is 19.61.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Eli Lilly and Company shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Eli Lilly and Company Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Eli Lilly and Company. The current sar is 615.83.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Eli Lilly and Company Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Eli Lilly and Company. The current rsi is 73.73. The current phase is Overbought in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Overbought in bull market: Short-term excessive buying, potential for pullback. Consider taking profits, be cautious of potential correction. -1
  • Trending up: The RSI is trending up. +1
Eli Lilly and Company Daily Relative Strength Index (RSI) ChartEli Lilly and Company Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Eli Lilly and Company. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Eli Lilly and Company price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Eli Lilly and Company Daily Stochastic Oscillator ChartEli Lilly and Company Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Eli Lilly and Company. The current cci is 252.89.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Eli Lilly and Company Daily Commodity Channel Index (CCI) ChartEli Lilly and Company Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Eli Lilly and Company. The current cmo is 60.78.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Eli Lilly and Company Daily Chande Momentum Oscillator (CMO) ChartEli Lilly and Company Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Eli Lilly and Company. The current willr is 0.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Eli Lilly and Company Daily Williams %R ChartEli Lilly and Company Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Eli Lilly and Company.

Eli Lilly and Company Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Eli Lilly and Company. The current atr is 16.18.

Eli Lilly and Company Daily Average True Range (ATR) ChartEli Lilly and Company Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Eli Lilly and Company. The current obv is 3,128.

Eli Lilly and Company Daily On-Balance Volume (OBV) ChartEli Lilly and Company Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Eli Lilly and Company. The current mfi is 63.65.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Eli Lilly and Company Daily Money Flow Index (MFI) ChartEli Lilly and Company Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Eli Lilly and Company.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-05-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-21WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-26STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-28STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-30MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-03CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-04SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-05STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-06STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-10DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-11MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-12STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-13STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-17STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-06-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-25CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-27STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-30CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-07-01STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-02STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-07-03STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-09CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-07-14WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-16CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-17CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-07-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-22STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-24SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-07-29STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-31MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-08-06STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-08-07ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-08-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-13RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-08-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-08-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-08-22STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-08-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-08-29STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-02STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-09-03STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-09-08STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-09-10CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-09-12STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-17STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-09-18STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-09-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-09-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-09-25CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-09-29STOCH SHORT EXITThe %K line crosses above the %D line.
2025-10-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

Eli Lilly and Company Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Eli Lilly and Company based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5073.728
Ma 20Greater thanMa 50644.795
Ma 50Greater thanMa 100628.242
Ma 100Greater thanMa 200648.019
OpenGreater thanClose698.600
Total2/5 (40.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Eli Lilly and Company with someone you think should read this too:
  • Are you bullish or bearish on Eli Lilly and Company? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Eli Lilly and Company? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Eli Lilly and Company

I send you an email if I find something interesting about Eli Lilly and Company.


Comments

How you think about this?

Leave a comment

Stay informed about Eli Lilly and Company.

Receive notifications about Eli Lilly and Company in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.